Osteonecrosis of jaw in patient with hormone-refractory prostate cancer treated with zoledronic acid

Karin B. Olson; C. Michael Hellie; Kenneth J. Pienta

doi:10.1016/j.urology.2005.03.028

Osteonecrosis of jaw in patient with hormone-refractory prostate cancer treated with zoledronic acid

Karin B. Olson, C. Michael Hellie, Kenneth J. Pienta

Research output: Contribution to journal › Article › peer-review

38 Scopus citations

Abstract

Intravenous bisphosphonates are widely used in the management of metastatic bone disease, as well as osteoporosis. Recent published reports have documented a possible link between treatment with intravenous bisphosphonates and osteonecrosis of the jaw. We report a case of osteonecrosis of the jaw in 1 patient with prostate cancer receiving both chemotherapy and intravenous zoledronic acid (Zometa). Bisphosphonates have been demonstrated to alter the normal bone microenvironment and appear to have direct effects on tumors as well. These changes may contribute to the development of osteonecrosis of the jaw, particularly after tooth extractions or other invasive dental procedures.

Original language	English (US)
Pages (from-to)	658.e1-658.e3
Journal	Urology
Volume	66
Issue number	3
DOIs	https://doi.org/10.1016/j.urology.2005.03.028
State	Published - Sep 2005
Externally published	Yes

ASJC Scopus subject areas

Urology

Access to Document

10.1016/j.urology.2005.03.028

Cite this

@article{1781de28044146638d527cd213b1d209,

title = "Osteonecrosis of jaw in patient with hormone-refractory prostate cancer treated with zoledronic acid",

abstract = "Intravenous bisphosphonates are widely used in the management of metastatic bone disease, as well as osteoporosis. Recent published reports have documented a possible link between treatment with intravenous bisphosphonates and osteonecrosis of the jaw. We report a case of osteonecrosis of the jaw in 1 patient with prostate cancer receiving both chemotherapy and intravenous zoledronic acid (Zometa). Bisphosphonates have been demonstrated to alter the normal bone microenvironment and appear to have direct effects on tumors as well. These changes may contribute to the development of osteonecrosis of the jaw, particularly after tooth extractions or other invasive dental procedures.",

author = "Olson, {Karin B.} and Hellie, {C. Michael} and Pienta, {Kenneth J.}",

year = "2005",

month = sep,

doi = "10.1016/j.urology.2005.03.028",

language = "English (US)",

volume = "66",

pages = "658.e1--658.e3",

journal = "Urology",

issn = "0090-4295",

publisher = "Elsevier Inc.",

number = "3",

}

TY - JOUR

T1 - Osteonecrosis of jaw in patient with hormone-refractory prostate cancer treated with zoledronic acid

AU - Olson, Karin B.

AU - Hellie, C. Michael

AU - Pienta, Kenneth J.

PY - 2005/9

Y1 - 2005/9

N2 - Intravenous bisphosphonates are widely used in the management of metastatic bone disease, as well as osteoporosis. Recent published reports have documented a possible link between treatment with intravenous bisphosphonates and osteonecrosis of the jaw. We report a case of osteonecrosis of the jaw in 1 patient with prostate cancer receiving both chemotherapy and intravenous zoledronic acid (Zometa). Bisphosphonates have been demonstrated to alter the normal bone microenvironment and appear to have direct effects on tumors as well. These changes may contribute to the development of osteonecrosis of the jaw, particularly after tooth extractions or other invasive dental procedures.

AB - Intravenous bisphosphonates are widely used in the management of metastatic bone disease, as well as osteoporosis. Recent published reports have documented a possible link between treatment with intravenous bisphosphonates and osteonecrosis of the jaw. We report a case of osteonecrosis of the jaw in 1 patient with prostate cancer receiving both chemotherapy and intravenous zoledronic acid (Zometa). Bisphosphonates have been demonstrated to alter the normal bone microenvironment and appear to have direct effects on tumors as well. These changes may contribute to the development of osteonecrosis of the jaw, particularly after tooth extractions or other invasive dental procedures.

UR - http://www.scopus.com/inward/record.url?scp=24144465755&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=24144465755&partnerID=8YFLogxK

U2 - 10.1016/j.urology.2005.03.028

DO - 10.1016/j.urology.2005.03.028

M3 - Article

C2 - 16140106

AN - SCOPUS:24144465755

SN - 0090-4295

VL - 66

SP - 658.e1-658.e3

JO - Urology

JF - Urology

IS - 3

ER -

Osteonecrosis of jaw in patient with hormone-refractory prostate cancer treated with zoledronic acid

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this